Rhia Ventures

Eli is a company focused on empowering women to manage their health by providing insights into their hormone profiles. It has developed an at-home device that monitors hormones using saliva samples, allowing for daily tracking of hormonal changes. Alongside the device, Eli offers an app that delivers personalized insights based on the collected data. The primary aim of Eli is to offer women a reliable and effective means to take charge of their fertility and contraception choices, thereby enhancing their overall health and well-being.

Founded in 2018, Twentyeight Health operates an online platform dedicated to improving women's reproductive and sexual health. It offers telemedicine services, including online doctor evaluations for birth control prescriptions, secure messaging with healthcare providers, and convenient home deliveries.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

YourChoice Therapeutics, Inc. is a biotechnology company based in Berkeley, California, founded in 2018. The company focuses on developing non-hormonal contraceptive products aimed at providing women with safe and effective birth control options. Its innovative technology is based on the concept of a "molecular condom," which utilizes an active compound to inhibit sperm motility, thereby preventing sperm from fertilizing the egg. This approach seeks to eliminate the risks and side effects commonly associated with traditional hormonal contraceptive methods, offering a promising alternative for those seeking safer birth control solutions.

Cayaba Care is a maternal health company focused on providing comprehensive support to medium and high-risk women throughout their pregnancy and postpartum journeys. The company employs a multidisciplinary approach, utilizing Maternity Navigators who are also certified doulas, to partner with members and enhance birth outcomes. Cayaba Care's services address a range of pregnancy-related concerns, including symptom relief, mental health support, breastfeeding assistance, and postpartum follow-up. By offering both virtual and in-person care, the company aims to alleviate stress and anxiety associated with pregnancy, ensuring that women experience a healthy and safe journey. Cayaba Care collaborates with commercial and Medicaid plans to implement standard and value-based care contracts, ultimately improving care quality and patient experience while achieving significant cost savings.

Fogarty Innovation is a nonprofit organization based in Mountain View, California, focused on advancing medical innovation to enhance human health. Founded in 2007, the organization supports promising innovators and researchers by transforming their creative ideas into practical solutions that improve patient care. It operates as an incubator, providing essential funding, mentorship, and research tools to facilitate the development of medical concepts from inception to application. Fogarty Innovation offers two key programs: one aimed at fostering innovation for startups and another dedicated to educating the next generation of inventors. Through these initiatives, Fogarty Innovation coordinates access to vital intellectual, physical, and financial resources to drive medical advancements.

Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.

Testmate Health is a medtech startup and award-winning spin-off of the University of Geneva in Switzerland. It has developed a smartphone-compatible platform test kit capable of diagnosing diseases based on identifiable DNA or RNA sequences without the need for a laboratory, delivering results in minutes at home. The initial product is a rapid urine self-test for the four most common sexually transmitted infections, designed to be used outside clinical settings and to provide a smartphone-scanable result that supports immediate access to treatment if needed. The platform uses DNA isothermal technology to detect infectious diseases with identifiable DNA, enabling home testing without laboratory submission. Further test kits for additional diseases are in development to empower users to monitor their health from home.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

Mae is a women's health care center providing pregnancy and postpartum support, tailored to women's needs. Mae is establishing a world in which high-quality, proactive care is the norm. Mae improves the quality of care for Black women by providing a trusted, digital-first health platform.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

Cirqle Biomedical is a Copenhagen-based biotech company focused on advancing women's health through innovative contraceptive solutions. The company is developing a non-hormonal contraceptive technology that utilizes mucus engineering principles to create a temporary barrier in cervical mucus, preventing sperm from entering the uterus. This approach aims to provide women with greater control over their reproductive choices without the use of traditional hormonal methods. By prioritizing women's freedom and quality of life, Cirqle Biomedical seeks to transform contraceptive options and enhance reproductive health.